The Pathways clinical trial into puberty blockers has been paused after the MHRA raised concerns about minimum age limits and unquantified long-term biological risks, with recruitment now suspended pending resolution.
The MHRA has raised new safety concerns about the PATHWAYS clinical trial investigating puberty blockers in young people with gender incongruence, pausing preliminary work until issues are resolved with sponsor King's College London.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05993260 |
Using Text Messages to Boost COVID-19 Vaccine Booking Rate |
COMPLETED | NA |
| NCT05238428 |
Understanding and Overcoming the Racial/Ethnic Inequalities in COVID-19 Vaccination Acceptance |
COMPLETED | NA |
